全文获取类型
收费全文 | 4850篇 |
免费 | 344篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 73篇 |
儿科学 | 136篇 |
妇产科学 | 104篇 |
基础医学 | 575篇 |
口腔科学 | 149篇 |
临床医学 | 488篇 |
内科学 | 936篇 |
皮肤病学 | 25篇 |
神经病学 | 721篇 |
特种医学 | 302篇 |
外科学 | 781篇 |
综合类 | 75篇 |
预防医学 | 274篇 |
眼科学 | 75篇 |
药学 | 268篇 |
中国医学 | 5篇 |
肿瘤学 | 232篇 |
出版年
2021年 | 66篇 |
2020年 | 48篇 |
2019年 | 89篇 |
2018年 | 88篇 |
2017年 | 61篇 |
2016年 | 61篇 |
2015年 | 83篇 |
2014年 | 98篇 |
2013年 | 126篇 |
2012年 | 173篇 |
2011年 | 226篇 |
2010年 | 111篇 |
2009年 | 131篇 |
2008年 | 203篇 |
2007年 | 223篇 |
2006年 | 237篇 |
2005年 | 208篇 |
2004年 | 176篇 |
2003年 | 183篇 |
2002年 | 172篇 |
2001年 | 156篇 |
2000年 | 178篇 |
1999年 | 142篇 |
1998年 | 97篇 |
1997年 | 82篇 |
1996年 | 77篇 |
1995年 | 55篇 |
1994年 | 46篇 |
1993年 | 53篇 |
1992年 | 122篇 |
1991年 | 103篇 |
1990年 | 109篇 |
1989年 | 101篇 |
1988年 | 114篇 |
1987年 | 106篇 |
1986年 | 86篇 |
1985年 | 80篇 |
1984年 | 64篇 |
1983年 | 50篇 |
1982年 | 35篇 |
1981年 | 36篇 |
1980年 | 36篇 |
1979年 | 51篇 |
1978年 | 26篇 |
1977年 | 32篇 |
1976年 | 33篇 |
1975年 | 37篇 |
1974年 | 41篇 |
1973年 | 39篇 |
1971年 | 40篇 |
排序方式: 共有5219条查询结果,搜索用时 15 毫秒
41.
42.
43.
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. 总被引:2,自引:2,他引:2
下载免费PDF全文
![点击此处可从《The American journal of pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
T. Luther V. Magdolen S. Albrecht M. Kasper C. Riemer H. Kessler H. Graeff M. Müller M. Schmitt 《The American journal of pathology》1997,150(4):1231-1244
uPAR (CD87), the receptor for the urokinase-type plasminogen activator (uPA) facilitates tumor cell invasion and metastasis by focusing uPA proteolytic activity to the cell surface. As uPAR exists in various molecular forms, it is desirable to use well defined antibodies for analyses of uPAR antigen expression in human malignant tumors by immunological methods. Therefore, twelve monoclonal antibodies (MAbs) directed against uPAR were generated by using nonglycosylated, recombinant human uPAR (spanning amino acids 1 to 284), expressed in Escherichia coli, as the immunogen. The reaction pattern of these MAbs with the immunogen and a series of carboxyl-terminally truncated versions of uPAR demonstrated that at least six different epitopes of uPAR are recognized. All MAbs reacted under reducing conditions in immunoblot analyses with E. coli-expressed uPA and also with highly glycosylated, functionally intact, recombinant human uPAR expressed in Chinese hamster ovary (CHO) cells. Seven of the MAbs recognized CHO uPAR under nonreducing conditions as well. By flow cytofluorometric analyses, three of these MAbs were shown to bind to native human uPAR present on the cell surface of monocytoid U937 cells with MAb IIIF10 being the best. Saturation of uPAR with uPA on U937 cells completely blocked interaction of MAb IIIF10 with uPAR (mapped epitope, amino acids 52 to 60 of domain I of uPAR). In turn, preincubation of U937 cells with MAb IIIF10 efficiently reduced binding of uPA to uPAR, indicating that the epitope detected by MAb IIIF10 is located within or closely to the uPA-binding site of uPAR, and thus, this site may be a target to influence uPA/uPAR-mediated proteolysis in tumors. Binding of MAbs IID7 or IIIB11 (mapped epitope, amino acids 125 to 132 of domain II of uPAR) to uPAR is not affected when uPAR is occupied by uPA. As these MAbs reacted strongly with cellular uPAR antigen in formalin-fixed paraffin-embedded tumor sections, the domain-II-specific antibodies IID7 and IIIB11 may be useful for immunohistochemical studies of uPAR expression in tissue remodeling processes in tumor invasion. In conclusion, we have devised well defined and epitope-mapped MAbs to uPAR that are highly specific tools for detection and targeting of uPAR in tumor tissue. 相似文献
44.
Comparison of API 20E, API rapid E, and API rapid NFT for identification of members of the family Vibrionaceae. 总被引:6,自引:3,他引:6
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Sixty isolates, from nine species of the family Vibrionaceae, were tested by the API 20E, API Rapid E, and API Rapid NFT systems. Results were compared with those obtained with standard biochemicals. Included were 7 Aeromonas caviae isolates, 27 Aeromonas hydrophilia isolates, 10 Aeromonas sobria isolates, 3 Plesiomonas shigelloides isolates, 3 Vibrio alginolyticus isolates, 3 Vibrio cholerae isolates, 1 Vibrio fluvialis isolate, 5 Vibrio parahaemolyticus isolates, and 1 Vibrio vulnificus isolate. The API 20E correctly identified all the isolates within 24 h. The API Rapid E correctly identified only 77%, misidentified 8%, and failed to identify 2% of the isolates in 4 h. The remaining 13% of the isolates gave a low selectivity identification, with one of the choices being correct. The API Rapid NFT correctly identified 87%, misidentified 5%, gave a low selectivity identification for 8% of the isolates, and in some instances, required up to 48 h of incubation. The API 20E is a valid system for use in the identification of the more commonly occurring members of the family Vibrionaceae and the most accurate and efficient of the three systems tested. 相似文献
45.
A computer model was designed as a relational database to assess breast cancer screening in a cohort of women where the growth and development of breast cancer originates with the first malignant cell. The concepts of thresholds for growth, axillary spread, and distant sites are integrated. With tumor diagnosis, staging was performed that includes clinical and sub-clinical states. The model was parameterized to have staging characteristics similar to data published by the Surveillance, Epidemiology, and End-Results (SEER) Program. Validation was accomplished by comparing simulated staging results with non-SEER sources, and simulated survival with independent clinical survival data. 相似文献
46.
Anti-HBs Cellular Immune Response in Kidney Recipients before and 4 Months after Transplantation
下载免费PDF全文
![点击此处可从《Clinical and Vaccine Immunology : CVI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Patricia Aguilar Edith Renoult Loraine Jarrosson Marie Nathalie Kolopp-Sarda Christine Prin Mathieu Gilbert C. Faure Mich
le Kessler Marie C. Bene Chantal Kohler Anne Kennel De March 《Clinical and Vaccine Immunology : CVI》2003,10(6):1117-1122
Patients with renal failure represent a population at risk for hepatitis B, since only 50 to 60% of them develop protective humoral responses after vaccination. As this could be due to an altered regulation of cellular immune responses, the objectives of the present study were to evaluate the proliferative abilities of lymphocytes from patients with chronic renal failure after stimulation in vitro with a mitogen (pokeweed mitogen [PWM]) or HBsAg. In order to differentiate between the immunodeficiency associated with renal failure and that due to immunosuppression posttransplantation, the same subjects were tested before and 4 months after kidney transplantation. The lymphoproliferation assay used was performed by flow cytometry, which is based on sequential analysis of the cell cycle and which allows analysis of cytokine production. Serologically, the group of 36 patients tested comprised 22% nonresponders, 30% poor responders, and 48% responders. Lymphocyte growth was observed for all patients after stimulation with PWM, indicating that these cells had the capacity to proliferate in vitro. The level of lymphoproliferation in response to PWM was significantly reduced after transplantation, yet both before and after transplantation, all serologic nonresponders developed cellular responses to at least two vaccines. No correlation between humoral and cellular responses was shown. Proliferating cells were lymphocytes, which mostly secreted interleukin 4 (IL-4) and IL-10 for the three serologic groups. This study suggests that even when repeated vaccination fails to induce significant antibody levels in patients with renal failure, specific HBs cellular responses develop, and these may prove to be efficient in protecting these patients against hepatitis B. 相似文献
47.
48.
Kessler HH Mühlbauer G Rinner B Stelzl E Berger A Dörr HW Santner B Marth E Rabenau H 《Journal of clinical microbiology》2000,38(7):2638-2642
Molecular detection of herpes simplex virus (HSV) DNA is recognized as the reference standard assay method for the sensitive and specific diagnosis of central nervous system infections caused by HSV. In this study, a molecular assay based on real-time PCR on the LightCycler (LC) instrument was evaluated and compared with a home-brew molecular assay. The detection limit of the LC assay was determined with 10-fold dilutions of plasmid pS4 with the SalI restriction fragment of the DNA polymerase gene and with the First European Union Concerted Action HSV Proficiency Panel. A total of 59 cerebrospinal fluid (CSF) specimens were investigated for the comparative study. With plasmid pS4, the detection limit of the LC assay was found to be 10(4) copies per ml, i.e., 12.5 copies per run. When samples of the First European Union Concerted Action HSV Proficiency Panel were tested, 2x10(3) to 5x10(3) HSV type 1 genome equivalents (GE) per ml, i.e., 2.5 to 6.3 GE per run, could consistently be detected. There was a correlation between the LC assay and the home-brew assay in 55 of 59 specimens. In conclusion, the LC assay allows very rapid detection of HSV DNA in CSF. It was found to be laborsaving and showed sufficient sensitivity. 相似文献
49.
Fully automated, internally controlled quantification of hepatitis B Virus DNA by real-time PCR by use of the MagNA Pure LC and LightCycler instruments 总被引:3,自引:0,他引:3
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Leb V Stöcher M Valentine-Thon E Hölzl G Kessler H Stekel H Berg J 《Journal of clinical microbiology》2004,42(2):585-590
We report on the development of a fully automated real-time PCR assay for the quantitative detection of hepatitis B virus (HBV) DNA in plasma with EDTA (EDTA plasma). The MagNA Pure LC instrument was used for automated DNA purification and automated preparation of PCR mixtures. Real-time PCR was performed on the LightCycler instrument. An internal amplification control was devised as a PCR competitor and was introduced into the assay at the stage of DNA purification to permit monitoring for sample adequacy. The detection limit of the assay was found to be 200 HBV DNA copies/ml, with a linear dynamic range of 8 orders of magnitude. When samples from the European Union Quality Control Concerted Action HBV Proficiency Panel 1999 were examined, the results were found to be in acceptable agreement with the HBV DNA concentrations of the panel members. In a clinical laboratory evaluation of 123 EDTA plasma samples, a significant correlation was found with the results obtained by the Roche HBV Monitor test on the Cobas Amplicor analyzer within the dynamic range of that system. In conclusion, the newly developed assay has a markedly reduced hands-on time, permits monitoring for sample adequacy, and is suitable for the quantitative detection of HBV DNA in plasma in a routine clinical laboratory. 相似文献
50.
S Safrin C Crumpacker P Chatis R Davis R Hafner J Rush H A Kessler B Landry J Mills 《The New England journal of medicine》1991,325(8):551-555
BACKGROUND AND METHODS. Most strains of herpes simplex virus that are resistant to acyclovir are susceptible in vitro to both foscarnet and vidarabine. We conducted a randomized trial to compare foscarnet with vidarabine in 14 patients with the acquired immunodeficiency syndrome (AIDS) and mucocutaneous herpetic lesions that had been unresponsive to intravenous therapy with acyclovir for a minimum of 10 days. The patients were randomly assigned to receive either foscarnet (40 mg per kilogram of body weight intravenously every 8 hours) or vidarabine (15 mg per kilogram per day intravenously) for 10 to 42 days. In the isolates of herpes simplex virus we documented in vitro resistance to acyclovir and susceptibility to foscarnet and vidarabine. RESULTS. The lesions in all eight patients assigned to foscarnet healed completely after 10 to 24 days of therapy. In contrast, vidarabine was discontinued because of failure in all six patients assigned to receive it. The time to complete healing (P = 0.01), time to 50 percent reductions in the size of the lesions (P = 0.01) and the pain score (P = 0.004), and time to the end of viral shedding (P = 0.006) were all significantly shorter in the patients assigned to foscarnet. Three patients had new neurologic abnormalities while receiving vidarabine. No patient discontinued foscarnet because of toxicity. Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42.5 days (range, 14 to 191) after foscarnet was discontinued. CONCLUSIONS. For the treatment of acyclovir-resistant herpes simplex infection in patients with AIDS, foscarnet has superior efficacy and less frequent serious toxicity than vidarabine. Once the treatment is stopped, however; there is a high frequency of relapse. 相似文献